SNO 2022 - Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day

Nov 16 - Nov 20, 2022 | TampaFLUS

LARVOL is not affiliated with Society for Neuro-Oncology 27th Annual Scientific Meeting and Education Day and all trademarks, logos, and brand names are property of their respective owners

Showing 133 abstracts linked to Trials

EXTH-12 - Preclinical and case study examination of the combination of the CLPP agonist ONC201 with the PI3K/AKT inhibitor paxalisib for the treatment of diffuse midline glioma.

  • Plenary

NIMG-34 - Quantification of glycolytic flux reduction in recurrent glioblastoma after EGFR inhibition using molecular MR-PET

CTIM-28 - Multilamellar mRNA lipid particles induce immunologic reprogramming in canine and human glioblastoma patients

CTNI-18 - First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma

CTNI-33 - CSNO2012001 study: A Phase III Trial on Adjuvant Temozolomide Chemotherapy with or without Interferon-alpha in Newly Diagnosed High-grade Gliomas

CTNI-60 - Preliminary results of binimetinib and encorafenib in adults with recurrent BRAF V600E-mutated high-grade glioma.

CTNI-61 - Clinical efficacy and predictive biomarkers of ONC201 in H3K27M-mutant diffuse midline glioma

CTNI-62 - Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors

NIMG-21 - Interim analysis of a phase II study of multiparametric MR-guided high-dose response-adaptive radiotherapy with concurrent temozolomide in patients with newly diagnosed glioblastoma